Table 3.

Cox proportional hazards models for spironolactone vs. placebo, stratified by clinical phenogroup

	Phenogroup 1		P- value	Phenogroup 2		P- value	Phenogroup 3		P- value
	HR	95% CI		HR	95% CI		HR	95% CI
Overall cohort
Primary endpoint	0.97	0.69–1.37	0.865	0.96	0.76–1.22	0.741	0.75	0.59–0.95	0.016
All-Cause Mortality or Heart Failure Hospitalization	1.10	0.74–1.64	0.626	0.94	0.72–1.22	0.641	0.82	0.60–1.12	0.214
Heart Failure Hospitalizations	0.76	0.45–1.27	0.301	0.96	0.72–1.29	0.799	0.67	0.53–0.90	0.007
All-Cause Mortality	1.09	0.75–1.58	0.663	0.88	0.69–1.12	0.294	0.89	0.65–1.21	0.448
Restricted to participants enrolled in the Americas
Primary endpoint	0.86	0.57–1.30	0.470	0.88	0.68–1.14	0.327	0.74	0.56–0.97	0.031
All-Cause Mortality or Heart Failure Hospitalization	1.06	0.61–1.87	0.827	0.85	0.64–1.13	0.270	0.90	0.63–1.29	0.573
Heart Failure Hospitalizations	0.81	0.49–1.34	0.418	0.93	0.69–1.26	0.640	0.70	0.52–0.95	0.023
All-Cause Mortality	1.19	0.69–2.05	0.526	0.80	0.61–1.05	0.104	0.86	0.60–1.23	0.410

CI=confidence interval; HR=hazard ratio